Sorrento Therapeutics Total Current Liabilities

Sorrento Therapeutics (SRNE) currently reports a total current liabilities of $260M as of June 2023. That compares with $150M in the prior-year period — up 82.3% year over year. Use the charts on this page to explore Sorrento Therapeutics's total current liabilities history and peer comparisons.

Sorrento Therapeutics's total current liabilities increased from $150M to $260M — a 82.3% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sorrento Therapeutics reported $260M in total current liabilities as of June 2023. That compares with $150M in the prior-year period — up 82.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $260M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sorrento Therapeutics, and consider following SRNE for alerts when major investors trade the stock.

Sorrento Therapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $260M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SRNE with unrelated industries.